Publications from the Centre for Immuno-Oncology
A phase I dose escalation and cohort expansion study of CB307, a trispecific Humabody® against PSMA, CD137, and albumin in patients with PSMA-positive solid tumors.
de Bono JS. et al, (2025), Clinical cancer research : an official journal of the American Association for Cancer Research
4-1BB agonist targeted to fibroblast activation protein α synergizes with radiotherapy to treat murine breast tumor models.
Garate-Soraluze E. et al, (2025), Journal for immunotherapy of cancer, 13
Author Correction: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.
Melero I. et al, (2025), Nature
Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020.
Ascierto PA. et al, (2025), Journal for immunotherapy of cancer, 13
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial.
Lopez J. et al, (2025), Nature medicine
Cross-priming in cancer immunology and immunotherapy.
Luri-Rey C. et al, (2025), Nature reviews. Cancer
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.
Melero I. et al, (2024), Nature
Regional and intratumoral adoptive T-cell therapy.
Olivera I. et al, (2024), Immuno-oncology technology, 24
Immunogenicity and Efficacy of Personalized Adjuvant mRNA Cancer Vaccines.
Berraondo P. et al, (2024), Cancer discovery, 14, 2021 - 2024
Targeting T-cell costimulation to the surface of tumor cells.
Eguren-Santamaría I. et al, (2024), Clinical cancer research : an official journal of the American Association for Cancer Research
Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma.
Ascierto PA. et al, (2024), NEJM evidence, 3
MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers.
Eguren-Santamaria I. et al, (2024), Journal for immunotherapy of cancer, 12
Reply to the Letter to the Editor "Reflections on the statistical methodology in nivolumab and ipilimumab therapy research" by S. Yang.
Melero I. et al, (2024), Annals of oncology : official journal of the European Society for Medical Oncology, 35, 827 - 828
Transcriptional and hormonal profiling uncovers the interactions between plant developmental stages and RNA virus infection.
Melero I. et al, (2024), The Journal of general virology, 105
Testing new anticancer drugs before curative locoregional therapies: MDICT 2024 recommendations
(2024), ESMO Open, 9, 103649 - 103649
Double-stranded RNA to mimic viral infection for cancer immunotherapy.
Martinez-Riaño A. et al, (2024), Clinical cancer research : an official journal of the American Association for Cancer Research
Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040.
Melero I. et al, (2024), Annals of oncology : official journal of the European Society for Medical Oncology, 35, 537 - 548
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials.
Segal NH. et al, (2024), Nature communications, 15
Spatially resolved tissue imaging to analyze the tumor immune microenvironment: beyond cell-type densities.
Lopez Janeiro A. et al, (2024), Journal for immunotherapy of cancer, 12